Patents
Literature
17 results about "Aprotinin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The drug aprotinin (Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is a small protein bovine pancreatic trypsin inhibitor (BPTI), or basic trypsin inhibitor of bovine pancreas, which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.
Liver function biochemical composite quality control product as well as preparation method and application thereof
ActiveCN119530340AComposite goodImprove stabilityMicrobiological testing/measurementPreparing sample for investigationBiotechnologyAprotinin
The invention discloses a liver function biochemical composite quality control product as well as a preparation method and application thereof. The quality control product comprises 12 analyte raw materials and the following non-analyte raw materials: 5 to 12 g / L of sodium chloride, 0.5 to 2 g / L of casein sodium salt, 5 to 20 g / L of mannitol, 0.05 to 0.2 g / L of Tween 20, 1 to 20 mg / L of bright aprotinin, 10 to 60 g / L of trehalose and 0.05 to 0.2 g / L of PC300. And matrix liquid: 20-80% of quality control substance matrix liquid and 20-80% of buffer solution. The liver function biochemical composite quality control product disclosed by the invention has high compositing property, contains 11 important liver function biochemical indexes, is excellent in component uniformity and stability, ensures the precision of each index, and meets the requirements of daily quality control.
Owner:GENEWELL BIOTECHNOLOGY CO LTD
Aqueous aprotinin-containing antiviral pharmaceutical composition
InactiveUS20240415944A1Dispersion deliveryPeptide/protein ingredientsDiseasePharmaceutical Substances
The invention relates to a new aqueous aprotinin-containing antiviral pharmaceutical composition with aprotinin activity from 50 KIU / ml to 950 KIU / ml, optionally containing excipients, for the prevention and treatment of acute respiratory viral infections (ARVI) (acute respiratory infection—ARI). The invention also relates to a new drug for the treatment and prevention of ARVI, comprising said composition in a form suitable for inhalation, nasal or drip use. The medicament can be a nasal spray, or a throat and mouth spray, placed in a vial or vial with a metering valve for a spray or with a dropper dispenser. The medicament can also be aqueous aprotinin-containing antiviral pharmaceutical composition, in a form suitable for inhalation, placed in a vial or vial, container or ampoule for inhalation by a nebulizer. The invention also relates to the use of VASPFC or a drug based on it for the prevention and treatment of ARVI. In particular, for the prevention and treatment of acute respiratory viral infections in patients infected with influenza viruses or coronaviruses, including SARS-CoV-2, as well as for the prevention and treatment of influenza pneumonia and coronavirus disease COVID-19.
Owner:IVASHCHENKO ANDREY ALEXANDROVICH +4
Aprotinin affinity chromatographic column as well as preparation method and application thereof
The invention provides a preparation method of an aprotinin affinity chromatographic column. Specifically, the aprotinin is used as a raw material and is coupled with CNBr activated agarose gel Focurose 4FF to prepare the aprotinin affinity chromatographic column. The coupling reaction in the preparation method is simple and easy to control, the reaction condition is mild, the operation is convenient, the repeatability is high, and industrial amplification is easy. The affinity column prepared by the invention can completely remove human urinary kallidinogenase in urokinase, and can be repeatedly used for multiple times.
Owner:JIANGSU AIDEA PHARMACEUTICAL CO LTD +1
A composite quality control product for liver function biochemistry, its preparation method and application
ActiveCN119530340BMicrobiological testing/measurementPreparing sample for investigationBiotechnologyMatrix solution
The present invention discloses a liver function biochemical composite quality control product and its preparation method and application. The quality control product includes 12 analyte raw materials and the following non-analyte raw materials: 5-12 g / L sodium chloride, 0.5-2 g / L casein sodium salt, 5-20 g / L mannitol, 0.05-0.2% Tween 20, 1-20 mg / L leupeptin, 10-60 g / L trehalose and 0.05-0.2% PC300; matrix liquid: 20-80% quality control product matrix liquid and 20-80% buffer. The liver function biochemical composite quality control product of the present invention has a high degree of complexity, contains 11 important liver function biochemical indicators, and performs well in terms of component homogeneity and stability, ensuring the precision of various indicators and meeting the needs of daily quality control.
Owner:GENEWELL BIOTECHNOLOGY CO LTD
Antiviral and bacteriostatic composition as well as preparation method and application thereof
The invention belongs to the technical field of bacteriostatic preparations, and particularly relates to an antiviral and bacteriostatic composition as well as a preparation method and application thereof. The antiviral and bacteriostatic composition is prepared from aprotinin, benzalkonium chloride, zinc gluconate, a plant extract, a flavoring agent and a solvent. The antibacterial rates of the antiviral and antibacterial composition to escherichia coli, staphylococcus aureus, candida albicans and pseudomonas aeruginosa are all higher than 99%, and the antiviral and antibacterial composition has a relatively strong antibacterial effect; the antiviral and bacteriostatic composition disclosed by the invention has a relatively strong inhibition effect on H3N2 and H1N1 influenza viruses; meanwhile, the safety is high, and if the eye drops accidentally enter the eyes, the eye drops have no irritation to the eyes and do not generate side effects of damaging the eyes. According to the antiviral and bacteriostatic composition, the peppermint essence and the aspartame in a specific ratio are combined as the flavoring agent, so that the antiviral and bacteriostatic composition is free of bitter and astringent feeling when being sprayed into the oral cavity and after being sprayed into the oral cavity, and also has proper sweetness.
Owner:NANJING GRITPHARMA CO LTD
Method for extracting unimodal urokinase from human urine
The invention relates to the technical field of separation and extraction of natural products, in particular to a method for extracting unimodal urokinase from human urine. The method sequentially comprises the following steps: human urine collection, silica gel chromatography, precipitation, aprotinin chromatography, pasteurization for virus inactivation, anisole chromatography, molecular sieve chromatography and freeze-drying. A novel purification process is designed, a specific purification technology is adopted to ensure that a final product shows a single peak in chromatographic analysis, the content of impurity protein in a high-purity product is extremely low, anaphylactic reaction and immunogenicity can be reduced, the medication safety of a patient can be improved, and the method can be directly used for development of a freeze-drying preparation or an injection and simplification of a downstream preparation process. The implementation of the scheme provided by the invention can promote the upgrading of the thrombolytic drug industry chain in China and improve the international competitiveness. The method has the advantages of high finished product purity, few impurities, simplicity and convenience in operation, concise extraction steps, reduced production time, high efficiency, small environmental pollution, low production cost and the like.
Owner:HENAN MEDSCIENCE PHARM CO LTD
Compounds, Pharmaceuticals, Formulations, and Methods for Treating and Preventing RNA Virus Infections and Associated Diseases
The present application is directed to compounds, pharmaceuticals, formulations, and methods for treating and preventing RNA virus infections, particularly infections in mammals. The present application also relates to treating and preventing diseases caused by RNA viruses. In preferred embodiments, the pharmaceuticals, formulations, and methods for treatment and prevention use liposomal aprotinin (Lip-APR).
Owner:IVACHTCHENKO ALEXANDRE VASILIEVICH +3
Oral ulcer pasting film and preparation method thereof
ActiveCN121622623ADigestive systemMacromolecular non-active ingredientsPolyvinyl alcoholPhosphorylation
The invention discloses an oral ulcer pasting film and a preparation method thereof, and belongs to the field of medicine, the oral ulcer pasting film comprises a double-layer film layer and a carrier layer loading the film layer; the double-layer film layer comprises an outer film layer and an inner film layer which are tightly attached to each other; the outer film layer is attached to the carrier layer; the inner membrane layer is prepared from the following components in parts by weight: 20 to 25 parts of phosphorylated chitosan, 15 to 20 parts of polyvinyl alcohol, 10 to 12 parts of glutin and 3 to 5 parts of a TG enzyme-aprotinin compound; the outer film layer is prepared from the following components in parts by weight: 35 to 40 parts of temperature-sensitive salt shrinkage polymer, 20 to 25 parts of carboxylated protein and 8 to 10 parts of glyceryl monostearate; the carrier layer is prepared from the following components in parts by weight: 70 to 80 parts of hydrophilic fiber-gelatin modifier, 6 to 8 parts of saliva stimulating factor and 15 to 20 parts of glycerol. The film of the present invention can maintain good structural flatness.
Owner:ONE STATE HEALTHCARE TECH (YUNNAN) CO LTD
Method for improving recombinant secretory expression of aprotinin
The invention discloses a method for improving recombinant secretory expression of aprotinin, which effectively promotes expression and secretion of recombinant protein to periplasmic space of escherichia coli by optimizing fusion protein coding gene of pelB signal peptide and antibacterial peptide, and improves the correct folding rate of target protein while improving the expression quantity so as to improve the enzymatic activity of the target protein. The method can be applied to recombinant preparation of aprotinin or aprotinin-containing products.
Owner:HANGZHOU HUNYI BIOTECHNOLOGY CO LTD
Preparation method of macromolecular d-dimer and application thereof
PendingCN122146830AImmunoglobulins against blood coagulation factorsBiological testingDimerAprotinin
The application discloses a preparation method and application of macromolecular D-dimer, and first finds that tannic acid or glutaraldehyde is used as a coagulation accelerator, and EDTA or aprotinin is used as a fibrinolysis terminator, so that the macromolecular D-dimer can be efficiently prepared in vitro; and a stable, repeatable and large-scale preparation process for the macromolecular D-dimer is first established. The application provides key raw materials and technical support for precise diagnosis and dynamic monitoring of thrombus, and has a wide application prospect.
Owner:NAT HEALTH COMMISSION INST OF SCI & TECH
Atomization preparation based on canine parvovirus specific nano antibody
The invention relates to the technical field of medicines, and particularly discloses an atomized preparation based on a canine parvovirus specific nano-antibody, which comprises a nano-antibody which is screened from an alpaca source immune antibody library and is specifically combined with canine parvovirus VP2 protein; a mucous membrane penetration enhancer: 0.1-0.5% (w / v) of a chitosan-citric acid derivative; the protease inhibitor compound is a composition of 0.05% (w / v) aprotinin and 0.02% (w / v) alpha-antitrypsin; the freeze-drying protection matrix is a glassy state forming agent composed of trehalose (5-8% w / v) and cane sugar (2-4% w / v) according to the proportion of 3: 1-1: 1; a targeting activator: 1-3 mM of intestinal alkaline phosphatase response type phosphate bond masking peptide; through the design of a delivery system, targeted coverage is realized by precisely regulating and controlling particle size distribution, so that 1-3-micron-grade particles are efficiently deposited in deep respiratory tract and intestinal lesion areas, and 5-8-micron-grade particles form a slow release library in oropharynx, so that the drug residence time is remarkably prolonged.
Owner:赣州职业技术学院
A dual-mode drug NANO-carrier bioconjugate combination
PCT designated stageWO2025155265A1Organic active ingredientsPeptide/protein ingredientsAprotininPharmaceutical drug
The present invention relates to an anti-cancer drug-loaded aprotinin nano-bioconjugate which is synthesized by using a microfluidic synthesis method in a single step using aprotinin, that is a multifunctional (moonlighting) protein acting as a nano-drug carrier for any compound / drug comprising anti-cancer properties.
Owner:BILKENT UNIVERSITESI ULUSAL NANOTEKNOLOJI ARASTIRMA MERKEZI
Compounds, pharmaceuticals, formulations, and methods for treating and preventing RNA virus infections and associated diseases
PCT designated stage expiredWO2025024432A1Peptide/protein ingredientsAntiviralsLipofectamineRNA Virus Infections
The present application is directed to compounds, pharmaceuticals, formulations, and methods for treating and preventing RNA virus infections, particularly infections in mammals. The present application also relates to treating and preventing diseases caused by RNA viruses. In preferred embodiments, the pharmaceuticals, formulations, and methods for treatment and prevention use liposomal aprotinin (Lip- APR).
Owner:ASAVI LLC +3
Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions
PendingUS20250064891A1Organic active ingredientsPeptide/protein ingredientsLeupeptinTransmembrane protein
Transmembrane proteases are necessary for HPIV3 fusion protein cleavage in the human lung. HPIV3 fusion protein cleavage in the human lung is not furin dependent as previously thought, but instead is facilitated by transmembrane proteases, typically targeting TMPRSS2 expression. Serine protease inhibitors may be used in this manner to treat HPIV in a patient. Particular serine protease inhibitors shown to be effective include nafamostat, camostat, aprotinin, and leupeptin. Method of treating HPIV use serine protease inhibitors as treating agents.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Physiological mixed gel precursor solution, gel material, preparation method of gel material and application of gel material in organoids
PendingCN119490949ACultivate applicableSuitable for clinical useHepatocytesSkeletal/connective tissue cellsTumor reductionECM Protein
The invention relates to the technical field of organoid culture, in particular to a physiological mixed gel precursor solution for organoid culture, which comprises a culture medium, spleen hydrogel, 0.8-1.2 mg / mL of type I collagen, 0.1-0.5 mg / mL of type IV collagen, 2.5-7.5 mg / mL of fibrinogen and 1-5 [mu] g / mL of aprotinin. The culture medium is a special liquid culture medium for the budding and growth of a vascular organ embryoid body; the spleen hydrogel is hydrogel taking animal spleen extracellular matrix as a raw material, and the concentration of the spleen hydrogel in the precursor solution is 2.5-12.5 mg / mL. According to the present invention, the physiological mixed gel precursor solution is gelatinized to obtain the matrix gel material, and the matrix gel material is used to wrap and culture the vascular organ embryoid body ball, such that the safety risk caused by the tumor-derived material can be reduced, the preparation cost can be reduced, and the technical support can be provided for the commercial preparation of the vascular organ.
Owner:ARMY MEDICAL UNIV
Recombinant aprotinin, its gene and method of production
The present application relates to a kind of recombinant aprotinin and its coding gene and preparation method, the preparation method is in the N end of the sequence of bovine aprotinin sequence and adds a sequence consisting of 21 amino acids, the recombinant aprotinin sequence is composed of 79 amino acids, molecular weight 8.812kD, isoelectric point 9.42.And a kind of rapid purification method is established, and the molecular weight of about 8.8kD of recombinant aprotinin can be quickly separated and purified by two-step chromatography, the activity recovery rate of whole purification process is high, specific activity >4.0EPU / mg, about 400mg of recombinant aprotinin pure product can be obtained per liter of fermentation liquor.The whole purification step is simple, the loss of target protein is less, the potency of obtained product is high, and the yield per liter of fermentation liquor is high, suitable for large-scale production application.
Owner:HEFEI MEINUO BIOTECHNOLOGY CO LTD
An oral ulcer patch and a preparation method thereof
ActiveCN121622623BImprove barrier propertiesImprove the protective effectDigestive systemMacromolecular non-active ingredientsPolyvinyl alcoholPhosphorylation
The application discloses an oral ulcer film and a preparation method thereof, and belongs to the medical field. The oral ulcer film comprises a double-layer film layer and a carrier layer of a loaded film layer. The double-layer film layer comprises a tightly adhered outer film layer and an inner film layer. The outer film layer is adhered to the carrier layer. The inner film layer comprises the following components in weight fractions: 20-25 parts of phosphorylated chitosan, 15-20 parts of polyvinyl alcohol, 10-12 parts of gelatin protein and 3-5 parts of a TG enzyme-antipain complex. The outer film layer comprises the following components in weight fractions: 35-40 parts of a temperature-sensitive salt condensation polymer, 20-25 parts of a carboxylated protein and 8-10 parts of glycerol monostearate. The carrier layer comprises the following components in weight fractions: 70-80 parts of a hydrophilic fiber-gelatin modifier, 6-8 parts of a saliva stimulating factor and 15-20 parts of glycerol. The film can maintain good structural flatness.
Owner:ONE STATE HEALTHCARE TECH (YUNNAN) CO LTD